Clinical trial
Olanzapine in the Treatment of Patients With Anorexia Nervosa
NCT00260962 · Ottawa Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00260962 |
|---|---|
| Title | Olanzapine in the Treatment of Patients With Anorexia Nervosa |
| Official title | Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study |
| Lead sponsor | Ottawa Hospital Research Institute, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anorexia Nervosa |
| Intervention type | Behavioral, Drug |
| Interventions | Olanzapine, Day Hospital |
| Enrollment | 34 |
| Start date | Sep 1, 2000 |
| Primary completion | Jul 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Dec 2, 2005 |
| Last update posted | Jan 30, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: